After raising $85m, SutroVax contracts Lonza to support vaccine development

By Melissa Fassbender contact

- Last updated on GMT

Approximately 18,000 older adults die each year from pneumococcal disease in the US, according to the CDC. (Image: Getty/Remains)
Approximately 18,000 older adults die each year from pneumococcal disease in the US, according to the CDC. (Image: Getty/Remains)
Lonza is supporting SutroVax’s development of its pneumococcal conjugate vaccine candidate through an end-to-end supply relationship.

The contract research development and manufacturing company (CDMO) Lonza Pharma & Biotech has been working with SutroVax since 2016, Karen Fallen, VP, business unit head, clinical development and manufacturing, Lonza, told us.

SutroVax's lead candidate is a pneumococcal conjugate vaccine (PCV) designed to prevent invasive pneumococcal disease caused by Streptococcus pneumonia. The biopharmaceutical company recently raised $85m in Series C financing to advance development.

“As Lonza and SutroVax’s partnership moves forward, we will continue to work closely together and ensure alignment on process and conjugate development, as well as microbial manufacturing scale-up for drug substance at Lonza's Visp, Switzerland site,” ​Fallen explained.

Lonza will advance the potentially best-in-class broad-spectrum PCV candidate through mid-stage clinical development. The CDMO also will provide formulation development and drug product manufacturing, Fallen added, which will ensure “a commercially viable process is in place for future product needs.”

Fallen said together the companies have “an opportunity to improve on the current standard of care for prevention of pneumococcal disease, and potentially introduce a truly transformative alternative that can replace existing treatments for both infants and adults.”

The currently market-leading vaccine – a 13-valent PCV, Prevnar 13 – has worldwide sales of approximately $6bn annually.

According to the Centers for Disease Control and Prevention (CDC), an estimated 900,000 Americans suffer from pneumococcal pneumonia each year, with up to 400,000 hospitalizations occurring annually.

Approximately 18,000 older adults die each year from pneumococcal disease in the US, according to the CDC.

Related news

Related products

show more

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers

Follow us

Products

View more